| 15.725 -0.095 (-0.6%) | 05-16 12:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.92 | 1-year : | 28.1 |
| Resists | First : | 20.48 | Second : | 24.05 |
| Pivot price | 20.23 |
|||
| Supports | First : | 14.68 | Second : | 12.22 |
| MAs | MA(5) : | 18.23 |
MA(20) : | 20.49 |
| MA(100) : | 30.31 |
MA(250) : | 37.07 |
|
| MACD | MACD : | -1.5 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 18.6 |
D(3) : | 27.2 |
| RSI | RSI(14): 31.5 |
|||
| 52-week | High : | 55.7 | Low : | 14.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BHVN ] has closed below the lower bollinger band by 3.2%. Bollinger Bands are 0.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.13 - 17.21 | 17.21 - 17.28 |
| Low: | 14.48 - 14.59 | 14.59 - 14.67 |
| Close: | 15.67 - 15.83 | 15.83 - 15.96 |
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Thu, 15 May 2025
Biohaven (BHVN) Stock Dips Significantly | BHVN Stock News - GuruFocus
Thu, 15 May 2025
Biohaven (BHVN) Shares Drop Over 17% Amid Market Activity | BHVN Stock News - GuruFocus
Thu, 15 May 2025
Biohaven stock slides as FDA delays drug review (BHVN:NYSE) - Seeking Alpha
Wed, 14 May 2025
First-Ever Treatment for Fatal Ataxia Disease Faces Critical FDA Decision: What's Next for Biohaven - Stock Titan
Wed, 14 May 2025
FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia - PR Newswire
Wed, 14 May 2025
Biohaven Ltd. Receives ‘Buy’ Rating Due to Promising Pipeline and Favorable Regulatory Progress - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 102 (M) |
| Shares Float | 85 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 92.1 (%) |
| Shares Short | 7,810 (K) |
| Shares Short P.Month | 7,490 (K) |
| EPS | -9.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -96.9 % |
| Return on Equity (ttm) | -198.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -582 (M) |
| Levered Free Cash Flow | -364 (M) |
| PE Ratio | -1.69 |
| PEG Ratio | 0 |
| Price to Book value | 3.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|